Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

The Lancet

Topics

Medicine

Pathology

Physiology

Internal Medicine

Endocrinology

Show all topics

DOI

10.1016/s0140-6736(05)66374-x

Other Formats

PDF